ALK Positive Inc. shared on LinkedIn:
“Join us for Clinical Trials Connect this Thursday, August 20, at 7:00 PM ET!
Dr. Ken Culver, ALK Positive’s Executive and Medical Director, will review a year of progress in ALK research and treatment, highlighting new clinical trials, publications, and important data updates from our medical committees and collaborators.
We will then hear directly from community members about their clinical trial experiences, including what motivated them to participate, what the experience was like, and what they learned.
Participants in TRI-611, gilteritinib, BNT-116, ivonescimab, neladalkib, and other trials are invited to share their perspectives.
- Thursday, August 20
- 7:00 PM ET
- Join us here.“
You can also read: FDA Grants Fast Track Designation to TRI-611 in ALK-Positive NSCLC
